Immatics N.V (IMTX) has a ROE of -50.26%, below the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow-50.26%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Immatics N.V (IMTX) currently reports a ROE of -50.26%. That is below the Healthcare sector average of 11.15%. Use the charts on this page to explore Immatics N.V's ROE history and peer comparisons.
Immatics N.V's ROE of -50.26% is lower than the Healthcare sector average of 11.15%. That is roughly 550.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Immatics N.V's current -50.26% should be judged against Healthcare norms (sector average: 11.15%) and against IMTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -50.26%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Immatics N.V, and consider following IMTX for alerts when major investors trade the stock.
Immatics N.V is classified in the Healthcare sector. On ROE, it currently shows -50.26% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IMTX with unrelated industries.